Results of Annual General Meeting

Sydney, 18 November 2025: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

All resolutions were passed and decided by way of poll. In respect to Resolution 1 "Adoption of Remuneration Report", the resolution passed with an excess of 75% voted in favour of the resolution.

-ENDS-

About the Sofra technology platform

Developed from a breakthrough discovery in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

Sofra technology has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease. In essence, the Sofra technology for autoimmune diseases replicates what is naturally occurring in the bodies of healthy people, but is either absent or too little in patients with autoimmune conditions.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Mr David Franks, Company Secretary of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward looking statement.

Disclosure of Proxy Votes

Noxopharm Limited

Annual General Meeting

Tuesday, 18 November 2025

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	44,058,694	42,101,389 95.56%	1,620,335 3.68%	35,681,306	336,970 0.76%	46,158,359 95.36%	2,244,585 4.64%	37,317,706	-
2 Re-election of Mr Boris Patkin as Director	P	54,399,707	49,771,475 91.49%	4,254,062 7.82%	34,378,106	374,170 0.69%	53,865,645 91.70%	4,878,312 8.30%	36,014,506	Carried
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	88,688,813	86,153,946 97.14%	2,137,078 2.41%	89,000	397,789 0.45%	92,532,385 97.74%	2,137,078 2.26%	89,000	Carried
4 Approval to Issue Securities under the Company's Employee Incentive Plan	P	44,985,393	40,228,393 89.43%	4,424,930 9.84%	34,754,607	332,070 0.74%	44,280,463 90.91%	4,424,930 9.09%	36,391,007	Carried
5 Approval of Issue of Incentive Securities to Dr Gisela Mautner, Managing Director of the Company	P	44,130,188	40,559,801 91.91%	3,238,317 7.34%	35,609,812	332,070 0.75%	44,611,871 89.03%	5,498,967 10.97%	35,609,812	Carried
6 Renewal of the Proportional Takeover Provisions within the Constitution	P	88,170,813	86,253,513 97.83%	1,546,030 1.75%	607,000	371,270 0.42%	91,981,183 98.35%	1,546,030 1.65%	1,231,250	Carried
7 Approval of Issue of Convertible Notes and Unlisted Options	P	24,603,141	21,220,441 86.25%	2,982,911 12.12%	35,693,811	399,789 1.62%	27,600,880 90.25%	2,982,911 9.75%	35,693,811	Carried
8 Approval of Issue of Convertible Notes and Unlisted Options to 4F Investments Pty Limited, an Associated Entity to Mr Fred Bart, Director of the Company	P	79,825,294	76,401,276 95.71%	3,052,748 3.82%	1,444,706	371,270 0.47%	82,753,196 96.44%	3,052,748 3.56%	1,444,706	Carried